{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/67ae1ccee54c8d1728893410?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Renishaw, Filtronic & British American Tobacco: The Companies and Markets Show","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1739463708265-d59aa1cb-6c4a-4fb2-b300-ea20295fa23f.jpeg?height=200","description":"<p>Christoper Akers kicks off the podcast with engineer <strong>Renishaw’s (RSW) </strong>results. From supply chain issues to long-standing murmurs of a sale, find out why investors were disappointed.</p><p><br></p><p>Valeria Martinez then unpacks<strong> </strong>designer and manufacturer <strong>Filtronic (FTC)</strong>, whose results were warmly received by the market. Listen to find out how the firm landed contracts with SpaceX, which has been a leading factor in its 300 per cent share price increase over the past year, and how it is expanding to grow its customer base.&nbsp;</p><p><br></p><p>Last up, we cover <strong>British American Tobacco (BAT)</strong>. Its latest results were not as strong as hoped, thanks to a struggling tobacco alternatives market and strong competition from <strong>Philip Morris (PM)</strong>. Mark Robinson explains all investors need to know.</p><p><br></p><p>This episode was recorded on 13 February. </p><p><br></p><p><strong>Timestamps</strong></p><p>1:30 Renishaw</p><p>9:24 Filtronic&nbsp;</p><p>25:06 British American Tobacco </p><p><br></p><p>Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit <a href=\"http://www.investorschronicle.co.uk/podcasttrial\" rel=\"noopener noreferrer\" target=\"_blank\">www.investorschronicle.co.uk/podcasttrial</a>&nbsp;</p><p>*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.</p><p><br></p><p><br></p>","author_name":"Investors' Chronicle"}